Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03879018 · ClinicalTrials.gov registry record · NA

Retraining Reaching in Cerebellar Ataxia

A NA study of Cerebellar Ataxia, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger.

Recruiting
Registry status
NA
Development phase
18
Enrollment target
1
Study location

NCT03879018 is a NA study of Cerebellar Ataxia that is actively recruiting participants, run by Hugo W. Moser Research Institute at Kennedy Krieger. The registered enrollment target is 18 participants, below the 347-participant average among 5 other Cerebellar Ataxia trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03879018, a NA study of Cerebellar Ataxia, is actively recruiting participants, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger.

RECRUITING
Registry status
NA
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to test for benefits of reinforcement based training paradigm versus standard practice over weeks for improving reaching movements in people with ataxia.

Conditions Studied

Interventions

  • BEHAVIORAL Reach training with visual feedback

Study Locations (1)

Maryland

  • Motion Analysis Lab in the Kennedy Krieger Institute - Baltimore

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2019-08-01
Est. Completion 2026-05-01
Phase NA

What the Registry Record Tells You About NCT03879018

The ClinicalTrials.gov registry entry for NCT03879018 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 347-participant average among 5 other Cerebellar Ataxia trials with a reported enrollment target (95% lower). The listed sponsor is Hugo W. Moser Research Institute at Kennedy Krieger, which has 73 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cerebellar Ataxia appearing as the primary indexed condition, and to 1 intervention - of which Reach training with visual feedback is the first listed.

NCT03879018 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT03879018 about?

NCT03879018 is a clinical study titled "Retraining Reaching in Cerebellar Ataxia". The purpose of this study is to test for benefits of reinforcement based training paradigm versus standard practice over weeks for improving reaching movements in people with ataxia.

What is the current status of trial NCT03879018?

This trial is currently recruiting. It is a NA study. The enrollment target is 18 participants. The study started on 2019-08-01. Estimated completion is 2026-05-01.

What conditions does trial NCT03879018 study?

This clinical trial studies the following conditions: Cerebellar Ataxia.

What interventions are being tested in trial NCT03879018?

The interventions under investigation include: Reach training with visual feedback (BEHAVIORAL).

Who is sponsoring clinical trial NCT03879018?

This trial is sponsored by Hugo W. Moser Research Institute at Kennedy Krieger, which has 73 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03879018 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cerebellar Ataxia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.